The projected revenue growth for Haemonetics indicates a positive outlook for the company's financial performance in 2024. This growth, especially on a reported basis, suggests that the company is expecting to see significant benefits from its operations and possibly strategic initiatives. The organic growth projection, although more modest, still points to underlying strength in the company's core business. This positive forecast is likely to be viewed favorably by investors, potentially leading to an increase in stock price in the short term.